Taysha Gene Therapies is a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations. Together with The University of Texas Southwestern Medical Center, Co. has a portfolio of gene therapy product candidates. Co.'s portfolio of gene therapy candidates targets neurological indications across three therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Co. owns worldwide rights to a clinical-stage intrathecally dosed AAV9 gene therapy program for the treatment of giant axonal neuropathy. The TSHA stock yearly return is shown above.
The yearly return on the TSHA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TSHA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|